Mega Lifesciences Public Company Limited (MEGA-R) — Cash Flow-to-Debt Ratio
Mega Lifesciences Public Company Limited (MEGA-R) has a Cash Flow-to-Debt Ratio of 0.11x as of June 2025, meaning its operating cash flow of ฿461.26 Million could theoretically repay 0% of its total liabilities (฿4.37 Billion) in one year. Explore MEGA-R long-term investments to assets to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mega Lifesciences Public Company Limited Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Mega Lifesciences Public Company Limited across 14 annual periods. Also explore total assets of Mega Lifesciences Public Company Limited for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Mega Lifesciences Public Company Limited (2011–2024)
Year-by-year debt coverage analysis for Mega Lifesciences Public Company Limited. For market capitalisation and broader financial context, see Mega Lifesciences Public Company Limited market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (THB) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.55x | ฿2.40 Billion | ฿4.33 Billion | ▲ +50.1% |
| 2023 | 0.37x | ฿1.93 Billion | ฿5.22 Billion | ▲ +8.6% |
| 2022 | 0.34x | ฿2.00 Billion | ฿5.87 Billion | ▼ -34.6% |
| 2021 | 0.52x | ฿2.73 Billion | ฿5.25 Billion | ▲ +47.1% |
| 2020 | 0.35x | ฿1.63 Billion | ฿4.61 Billion | ▲ +3.0% |
| 2019 | 0.34x | ฿1.50 Billion | ฿4.36 Billion | ▲ +45.9% |
| 2018 | 0.24x | ฿919.36 Million | ฿3.91 Billion | ▼ -11.8% |
| 2017 | 0.27x | ฿927.00 Million | ฿3.48 Billion | ▼ -31.0% |
| 2016 | 0.39x | ฿1.26 Billion | ฿3.26 Billion | ▲ +108.0% |
| 2015 | 0.19x | ฿609.12 Million | ฿3.28 Billion | ▼ -17.0% |
| 2014 | 0.22x | ฿614.22 Million | ฿2.74 Billion | ▲ +36.6% |
| 2013 | 0.16x | ฿465.77 Million | ฿2.84 Billion | ▲ +20.2% |
| 2012 | 0.14x | ฿342.02 Million | ฿2.51 Billion | ▲ +0.8% |
| 2011 | 0.14x | ฿266.67 Million | ฿1.97 Billion | — |